UBS AM’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-55,460
| Closed | -$7.56M | – | 2613 |
|
|
2020
Q3 | $7.56M | Buy |
55,460
+2,024
| +4% | +$215K | ﹤0.01% | 1019 |
|
|
2020
Q2 | $5.16M | Buy |
53,436
+4,979
| +10% | +$415K | ﹤0.01% | 1106 |
|
|
2020
Q1 | $2.27M | Buy |
48,457
+3,370
| +7% | +$216K | ﹤0.01% | 1354 |
|
|
2019
Q4 | $3.29M | Buy |
45,087
+3,330
| +8% | +$202K | ﹤0.01% | 1378 |
|
|
2019
Q3 | $2.18M | Buy |
41,757
+4,626
| +12% | +$246K | ﹤0.01% | 1581 |
|
|
2019
Q2 | $1.86M | Buy |
37,131
+10,799
| +41% | +$526K | ﹤0.01% | 1632 |
|
|
2019
Q1 | $1.37M | Buy |
26,332
+5,905
| +29% | +$272K | ﹤0.01% | 1690 |
|
|
2018
Q4 | $998K | Buy |
20,427
+1,246
| +6% | +$68.6K | ﹤0.01% | 1758 |
|
|
2018
Q3 | $1.25M | Buy |
19,181
+1,758
| +10% | +$103K | ﹤0.01% | 1718 |
|
|
2018
Q2 | $865K | Buy |
17,423
+5,390
| +45% | +$261K | ﹤0.01% | 1873 |
|
|
2018
Q1 | $587K | Buy |
+12,033
| New | +$626K | ﹤0.01% | 1973 |
|
UBS AM's MYOK Position: Q4 2020 in Review
UBS AM sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 55,460 shares — an estimated $7.56M sold.
UBS AM first reported a position in MYOK in Q1 2018 and held it in 11 quarters. The position peaked at $7.56M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- UBS AM reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- UBS AM sold 55,460 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $7.56M.
- UBS AM first reported a position in MyoKardia, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
- UBS AM's MyoKardia, Inc. Common Stock position peaked at $7.56M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.